PARP1 and pachyonychia congenita: While PARP inhibitors targeting PARP1 have shown promise for advanced/metastatic PC (Zhu et al., 2020), challenges including adverse effects and drug resistance limit their clinical utility (Golan et al., 2019; Kaufman et al., 2015; Lord and Ashworth, 2017; Shroff et al., 2018).